Table E1.
Patient with RA disease activity and treatment from the longitudinal study
| Responder (R) or nonresponder (NR) | Concomitant treatment | DAS28 baseline | DAS28 3 mo |
|---|---|---|---|
| R | Nil | 5.64 | 3.89 |
| R | Nil | 6.08 | 2.11 |
| R | Nil | 4.13 | 2.55 |
| R | Nil | 7.2 | 4.52 |
| R | Nil | 5.17 | 1.63 |
| R | Nil | 5.18 | 2.62 |
| R | LEF, HCQ | 5.18 | 3.67 |
| R | MTX | 5.32 | 2.56 |
| R | MTX | 5.27 | 2.14 |
| R | MTX, SSZ | 5.92 | 3 |
| R | MTX, Pred | 7.15 | 4.12 |
| R | MTX, SSZ | 5.61 | 3.27 |
| R | MTX, HCQ | 5.37 | 3.98 |
| R | MTX, HCQ, SSZ | 6.45 | 5.19 |
| NR | Nil | 5.17 | 5.75 |
| NR | LEF | 5.62 | 4.89 |
| NR | Pred, SSZ | 6 | 5.19 |
| NR | MTX | 5.1 | 4.36 |
| NR | MTX, Pred | 5.16 | 5.83 |
Nil indicates that the patient was not taking any disease-modifying antirheumatic drug.
DAS28 = 0.56 × √(tender28) + 0.28 × √ (swollen28) + 0.70 × ln(CRP) + 0.014 × VASpatient. See https://www.das-score.nl/das28/en/introduction-menu.html. All patients who were taking MTX were on a constant dose for the last 5 months before the sample was taken.
CRP, C-reactive protein; HCQ, hydroxychloroquine; LEF, leflunomide; MTX, methotrexate; Pred, prednisolone; SSZ, sulphasalazine.